首页 > 市场调查报告书 > 製药

非专利药生技仿製药

市场调查报告书

商品编码

1392045

Humira 生物相似药市场：按产品类型、按适应症、按配销通路、按患者年龄、按地区

Humira Biosimilar Market, By Product Type (Biosimilar Humira, and Interchangeable Biosimilar Humira), By Indication, By Distribution Channel, By Patient Age, By Geography

出版日期: 2023年11月01日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计全球修美乐生物相似药市场在不久的将来将显着成长，市场规模从2023年的7.721亿美元扩大到2030年的38.714亿美元，复合年增长率为25.9%。

报告范围		报告详情
基准年	2022年	2023年市场规模	7.721 亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期复合年增长率	25.90%	2030年市场规模预测	38.714 亿美元

图 1. Humira 生物相似药全球占有率(%)，按地区划分，2023 年

Humira 是生物製药用于治疗干癣和类风湿性关节炎等自体自体免疫疾病的生物製剂，是世界上最受欢迎的生物製药。 Humira在部分地区的专利保护到期后，生物相似药在安全性、有效性和品质方面是高度相似的生物製药复製品。这些生物相似药可能会增加竞争并导致价格下降。生物相似药可以透过提供更经济的治疗选择来帮助降低成本并改善患者获得基本药物的机会。生物相似药已被证明与原始生物製药一样有效和安全，使其成为患有干癣和类风湿性关节炎等疾病的患者的可行选择。此外，生物相似药的出现促进了製药业的创新，鼓励製造商在不影响品质的情况下开发更实惠的治疗方案。这种市场竞争降低了价格，增加了患者的可近性，并最终改善了医疗保健结果。此外，生物相似药的引入增加了患者的选择和自主权，使患者能够根据自己的具体需求选择最合适且最具成本效益的治疗方法。

市场动态

专利到期、成本降低、自体免疫疾病盛行率上升以及有利的法规环境是预测期内推动全球 Humira 生物相似药市场成长的主要因素。

例如，北美引领生物相似药采用市场，多种 Humira 生物相似药核准和推出。该地区拥有支持采用生物相似药、增加市场竞争并可能降低成本的法律体制和政策。

然而，复杂的监管流程、智慧财产权和专利诉讼、医生和患者意识等预计将阻碍全球脑血管造影市场在预测期内的成长。

本研究的主要特点

本报告对全球 Humira 生物相似药市场进行了详细分析，并列出了以 2022 年为基准年的预测期（2023-2030）的市场规模和復合年增长率。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
该报告根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球 Humira 生物相似药市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
Humira 生物相似药全球市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球 Humira 生物相似药市场的各种策略矩阵，将有助于相关人员做出决策。

公司简介
- Amgen Inc.
- Samsung Bioepis Co.
- Sandoz International GmbH（Novartis AG）
- Mylan NV
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences
- Biogen Inc
- AbbVie Inc
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck &Co
- Viatris Inc.
- Alvotech
- Analysts'Views

第11章章节

参考
调查方法
关于出版商

简介目录

Product Code: CMI5925

Global humira biosimilar market is projected to witness substantial growth in the near future, and the market size is expected to increase from US$ 772.1 Mn in 2023 to US$ 3,871.4 Mn by 2030, with a compound annual growth rate (CAGR) of 25.9%.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 772.1 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	25.90%	2030 Value Projection:	US$ 3,871.4 Mn

Figure 1. Global Humira Biosimilar Share (%), By Region, 2023

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market

Global Humira Biosimilar Market Detailed Segmentation:

By Product Type:
- Biosimilar Humira (Adalimumab)
- Interchangeable Biosimilar Humira
By Indication:
- Rheumatoid Arthritis
- Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Other Autoimmune Conditions
By Patient Age:
- Adult Patients
- Pediatric Patients
- Geriatric Patients
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Top companies in Global Humira Biosimilar Market
- Amgen
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences, Inc.
- Biogen Inc.
- AbbVie Inc.
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- Viatris Inc.
- Alvotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Patent expiration
- Cost savings
- Increasing prevalence of autoimmune diseases
- Favorable regulatory environment
Market Restraints
Market Opportunity
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers Acquisitions, and Collaborations

4. Global Humira Biosimilar Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Humira Biosimilar Market, By Product Type, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Biosimilar Humira (Adalimumab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Interchangeable Biosimilar Humira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Humira Biosimilar Market, By Indication, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Juvenile Idiopathic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Other Autoimmune Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Humira Biosimilar Market, By Patient Age, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Humira Biosimilar Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

9. Global Humira Biosimilar Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2023-2030, (US$ Mn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Samsung Bioepis Co.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences
- Biogen Inc
- AbbVie Inc
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co
- Viatris Inc.
- Alvotech
- Analysts' Views

11. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

Humira 生物相似药市场：按产品类型、按适应症、按配销通路、按患者年龄、按地区